可孚醫療(301087.SZ):目前已實現血壓計等核心產品自主生產 自產收入佔比例約55%
格隆匯1月11日丨可孚醫療(301087.SZ)在接待機構投資者調研時表示,2023年公司有序推進了長沙和湘陰生產基地的產品結構調整和新產品投產工作,不斷豐富自主生產品類和產能。目前公司已實現血壓計、血糖儀、體温計、輪椅、護理牀、製氧機、霧化器、敷料/敷貼、口罩等核心產品的自主生產,自產收入佔比例約55%。
隨着自產規模的提升,公司毛利率有一定提升空間,產品品質將持續提升,為消費者提供更高質量、更具性價比的產品。未來,公司將進一步加強生產計劃管理,有序增加新產品品類的投產,優化產品結構,改進生產工藝,提升現有生產線的產能利用效率,降低生產成本。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.